Invention Grant
- Patent Title: Modified nucleic acid
-
Application No.: US14439460Application Date: 2013-10-30
-
Publication No.: US09725474B2Publication Date: 2017-08-08
- Inventor: Shumpei Murata , Shinichi Masada , Naoki Miyamoto , Tadashi Umemoto
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Priority: JP2012-241286 20121031
- International Application: PCT/JP2013/079389 WO 20131030
- International Announcement: WO2014/069520 WO 20140508
- Main IPC: C07F9/6561
- IPC: C07F9/6561 ; C07H21/02 ; C07F9/6558 ; C07H21/00 ; C07D239/54 ; C07D473/34 ; C07F9/6512

Abstract:
Provided is an oligonucleic acid analog which contains, as at least one structural unit thereof, a modified nucleic acid monomer compound which is a ring-open nucleoside having a cleaved carbon-carbon bond between the 2′ and 3′ positions and a substituent hydroxymethyl group at the 4′ position. When used as siRNA, the oligonucleic acid analog exhibits superior biological stability and target gene expression inhibiting activity. The oligonucleic acid analog can be used in antisense methods, ribozyme methods, and decoy methods, etc., can be used as a nucleic acid aptamer, and can also be used as a nucleic acid probe or molecular beacon, etc., or in genetic diagnostics, etc.
Public/Granted literature
- US20160016983A1 New Modified Nucleic Acid Public/Granted day:2016-01-21
Information query